Skip to main content
. 2022 Jan 28;12:748403. doi: 10.3389/fonc.2022.748403

Figure 1.

Figure 1

Overexpression of PFKFB3 in ovarian cancer is correlated with metastasis and poor prognosis. (A) Representative images of PFKFB3 expression in (i) normal ovarian tissue, (ii) serous, (iii) mucinous, (iv) endometrioid and (v) clear cell subtypes of tumor samples on ovarian cancer TMA (OVC1021, Biomax) by IHC staining (scale bar, 100 μm). The insets highlight regions with higher magnification. (B) Association of PFKFB3 with stage/grade/histotype in ovarian cancer. The graphs for stage and grade encompass all four histotypes. (C) Representative images of IHC staining for PFKFB3 expression in ovarian primary tumors (i, iii) and their metastatic foci (ii, iv; scale bar, 100 μm). (D) Bar chart showing PFKFB3 staining in 13 pairs of tissues. (E) Relative PFKFB3 mRNA expression in HOSE 11-12, primary cancer cells and matched ascites cancer cells from high-grade serous ovarian cancer, determined by qPCR. (F) PFKFB3 expression in HOSE 11-12 and ovarian cancer cell lines (SKOV3, OVCAR3, and TOV112D) at the mRNA level, determined by qPCR. (G) (left) Overall and (right) progression-free survival rates were analyzed with the log-rank test for PFKFB3 high/low groups of ovarian cancer patients obtained from GSE26193 (n = 107), by using the Kaplan-Meier plotter. (*p < 0.05, **p < 0.01; n.s., not significant).